Quantum BioPharma Ltd. Releases Form 6-K: January 2024 Financial Insights

Here are the key insights extracted from the provided section of the financial report:

1. Document Type and Filing Details:

• Type: Form 6-K
• Commission File Number: 001-39152
• Filing Date: January 14, 2025
• Reporting Period: For the month of January 2024.

2. Company Information:

• Registrant Name: Quantum BioPharma Ltd.
• Address: 55 University Ave., Suite 1003, Toronto, Ontario, M5J2H7, Canada.
• Nature of Filing: Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

3. Signatory:

• Name: Donal Carroll
• Position: Chief Financial Officer (CFO)
• Signature: The document is duly signed by the CFO, indicating that the information reported is authorized.

4. Exhibits:

• Exhibit 99.1: A press release is included as part of the filing, which may contain additional significant information regarding the company's operations or announcements.

5. Compliance: The registrant indicates its filing intentions regarding annual reports under Form 20-F or Form 40-F, with a check mark next to Form 20-F, suggesting that this is the primary reporting format used.

This summary contains the essential information for stakeholders to understand the context and content of the financial report filed by Quantum BioPharma Ltd.